Vera Therapeutics Inc (VERA) - Total Liabilities
Based on the latest financial reports, Vera Therapeutics Inc (VERA) has total liabilities worth $122.04 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VERA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Vera Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Vera Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Vera Therapeutics Inc asset portfolio.
Vera Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Vera Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wienerberger AG
VI:WIE
|
Austria | €3.47 Billion |
|
Compagnie Financiere Tradition
SW:CFT
|
Switzerland | CHF648.95 Million |
|
VGP NV
BR:VGP
|
Belgium | €2.54 Billion |
|
Cadeler A/S
NYSE:CDLR
|
USA | $1.85 Billion |
|
Douzone Bizon Co Ltd
KO:012510
|
Korea | ₩517.29 Billion |
|
SAGILITY INDIA LIMITED
NSE:SAGILITY
|
India | Rs28.62 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$8.04 Billion |
|
Zhongshan Broad-Ocean Motor Co Ltd
SHE:002249
|
China | CN¥9.00 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Vera Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See VERA equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vera Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vera Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Vera Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $130.21 Million | +65.82% |
| 2024-12-31 | $78.53 Million | +6.32% |
| 2023-12-31 | $73.86 Million | +35.46% |
| 2022-12-31 | $54.53 Million | +285.19% |
| 2021-12-31 | $14.16 Million | -90.16% |
| 2020-12-31 | $143.90 Million | +243.20% |
| 2019-12-31 | $41.93 Million | -- |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more